Italy · Delayed Price · Currency is EUR Philogen Earnings Call Transcripts
Fiscal Year 2025
-
Reported EUR 230 million net profit and EUR 380 million cash for 2025, with a EUR 0.70 dividend per share. Advanced key oncology programs, including Nidlegy and Fibromun, and secured major licensing deals. Regulatory submissions and pivotal trials are on track.
-
A transformative licensing deal with Racebio has significantly strengthened liquidity, enabling expanded investment in late-stage clinical programs and infrastructure. Key trials in oncology and dermatology are progressing, with major data readouts and regulatory milestones expected in 2025–2026.
Fiscal Year 2024
-
2024 saw revenues triple to €77.5M, driven by contract income, with EBITDA over €40M and net profit of €45M. Major clinical progress was made in oncology programs, with pivotal trial readouts expected in 2025 and a strong cash position of €113.7M.
-
Major clinical milestones achieved in skin, brain, and soft tissue cancers, with pivotal trials completed or nearing completion and regulatory filings advancing in both Europe and the US. Small molecule pipeline shows strong potential to outperform current market leaders in prostate cancer.
-
Announced a global commercialization deal with Sun Pharma for Nidlegy and Fibromun, with strong clinical progress in melanoma, non-melanoma skin cancers, and soft tissue sarcoma. Financials show increased expenses and a net loss, but liquidity remains strong and positive year-end results are expected.
-
Targeted cancer therapies show strong clinical progress, with Nidlegy doubling recurrence-free survival in melanoma and high response rates in BCC and SCC. Regulatory filings are advancing, new trials are launching, and commercial partnerships are being pursued for global market access.